Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Idaho Sci-Tech Network.
Press releases published on May 8, 2025

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage …

Glimpact Launches Global Impact Score – A Free Online Tool to Measure and Reduce the Environmental Footprint of Apparel, Revealing a New Vision of the Challenges of the Fashion Industry’s Ecological Transition
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Glimpact, the first platform for analyzing the overall systemic environmental impact of products and organizations, today launched Global Impact Score, North America’s first publicly accessible online tool to …

Cue Biopharma to Host Virtual Investor Event on May 15, 2025
Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a …

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment …

Infinidat Wins 2025 Global InfoSec Awards for Cyber Resilience, Cyber Storage, and Ransomware Recovery from Cyber Defense Magazine
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Infinidat, a leading provider of enterprise storage solutions, today announced that the company has won three Global InfoSec Awards from Cyber Defense Magazine, a leading information security magazine. The …

Scality named a 2025 Stevie Award winner
SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Scality, a global leader in cyber-resilient storage software for the AI era, announced today that its ARTESCA 3.0 solution earned a Gold Stevie® Award in the Cloud Storage …

Xunlei Limited Schedules 2025 Unaudited First Quarter Earnings Release on May 15, 2025
SHENZHEN, China, May 08, 2025 (GLOBE NEWSWIRE) -- Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today announced that it plans to release its unaudited financial …

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide
Worldwide first artificial Human Platelet Lysate (HPL) solution – a key ingredient for the research …

Remote Monitoring and Control Provider Acorn’s Q1’25 EPS Rose to $0.19 vs. $0.03 on 45% Higher Revenue; Investor Call Today at 11am ET
WILMINGTON, Del., May 08, 2025 (GLOBE NEWSWIRE) -- Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control solutions for backup generators, gas pipelines and other critical infrastructure assets, announced results for its first …

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI …

OrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo Ventures
OXFORD, England and MADISON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd., a leading organ medical technology company, completed a second closing of its private placement with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland …

Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine’s potential across degenerative disease indications …

Kamari Pharma Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology and the International Pachyonychia Congenita Consortium Symposium
Preclinical results presented demonstrate KM-023 is a highly effective and selective oral TRPV3 inhibitor KM-023 normalized cells proliferation and differentiation in 3D pachyonychia congenita skin model and significantly reduced itch behavior and …

CoreCard Corporation Reports First Quarter 2025 Results
NORCROSS, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, …

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a …

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the …

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025 Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary …

Cronos Group Reports 2025 First Quarter Results
Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Industry-leading balance sheet with $838 million in …

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential …

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell …